March 02, 2023 — 10:00 am EST

      Written by
                        RTTNews.com for                             
        




RTTNews ->


(RTTNews) - Intellia Therapeutics, Inc. (NTLA) shares are gaining more than 7 percent on Thursday morning trade after the company announced FDA clearance of an investigational new drug application for NTLA - 2002 for the treatment of type 1 or type 2 hereditary angioedema. 
The clinical stage genome editing company said NTLA-2002 is an in vivo CRISPR-based investigational therapy.
Intellia said its Phase 1 study demonstrated deep, dose-dependent reductions in plasma kallikrein and robust reductions in patient HAE attacks.
Currently, shares are at $43.79, up 7.47 percent from the previous close of $40.75 on a volume of 694,173. 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2023, Nasdaq, Inc. All Rights Reserved.










To add symbols:


These symbols will be available throughout the site during your session.
To add symbols:


These symbols will be available throughout the site during your session.